49.2 F
New York
Monday, November 30, 2020

BeiGene [NASDAQ: BGNE] Signs Licensing Deal For Neutralizing COVID-19 Antibodies With Singlomics

Must read

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...

Athene Enters Into An Agreement With Hertz To Buy Donlen Corp.

Athene Holdings ltd. entered into a deal to buy Donlen corporation from Hertz Global Holdings Inc. Hertz's fully own Donlen Corporation. The stock...

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

BeiGene, Ltd. [NASDAQ: BGNE] and Singlomics Biopharmaceuticals, Ltd both entered into an exclusive license agreement for neutralizing COVID-19 antibodies.

The license agreement will allow BeiGene to develop, manufacture, and commercialize Singlomics’ investigational anti-COVID-19 antibodies, including DXP-593 and DXP-604 globally. 

Shares of BeiGene had plummeted 0.63%, or down -1.58 during the trading of Wednesday. It has a closing price of $249.26. BeiGene had recorded the trading volume of 128.02K as compared to the average volume of 272.07K.

In the past 52-weeks of trading BeiGene’s stocks have changed between the low and high of $114.41-$256.01, respectively. It has exhibited the highest change of 117.87% from its 52-weeks low and the lowest change of -2.64% from its 52-weeks high.

If we turn our focus o its profitability, it has return on assets (ROA), return on equity (ROE), and return on investment (ROI) of -48.70%, -73.50%, and -85.60%, respectively.

Its Gross Margin is 70.40%. Continuing to look at its liquidity, it has a current ratio of 6.20. Similarly, its quick ratio is 6.10. This company has a total market capitalization of 21.75 billion.

Singlomics Biopharmaceutical has recognized multiple antibodies by using single-cell sequencing of convalescent blood samples from recovered patients with COVID-19.

It has shown the ability to neutralize the SARS-CoV-2, the virus that caused COVID-19 in the pre-clinical studies. Singlomics strived to find the potent neutralizing antibodies to develop a treatment.

BeiGene has a strong background in clinical development and the new agreement will give an opportunity to the companies to develop the potential treatment for COVID-19.

A phase 1 clinical trial is anticipated to commence in September with up to 30 healthy patients. Additionally, the phase 1/2 multinational trial with mild to moderate COVID-19 will also commence in October.

Singlomics will get an upfront payment. It will also receive payments upon the achievement of regulatory and commercial milestones.

Furthermore, Singlomics will also get tiered royalties, up to double-digits, on future product sales.

More articles

Latest article

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...

Ford [NYSE: F ] Booked Ultra-Cold Freezers To Ensure Autoworkers Access To The Covid-19 Vaccine

Ford Motors Co. revealed recently that to stock Pfizer Inc Covid-19 vaccine securely, it has requested 12 of the ultra-cold freezer. The automaker...

Transdigm [NYSE: TDG] Enters Into An Agreement To Buy Cobham Aero Connectivity

Transdigm group incorporation , the global aircraft component manufacturer and provider declared the acquisition of Cobham Aero Connectivity, the top supplier of antennas and...

LCI Industries’ [NYSE: LCII] Subsidiary Lippert Components Acquires Challenger Door

LCI Industries has revealed that its unit Lippert Components has completed the acquisition of Challenger Door, Inc. This acquisition will provide the opportunity...

Blackstone Group [NYSE: BX] Finalizes Recapitalization Of BioMed Realty

The Blackstone Group Inc. has disclosed today that Blackstone Real Estate Partners VIII L.P.  has executed the deal related to BioMed Realty. The...

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate...

Scienjoy [NASDAQ: SJ] Inks Agreement With China Mobile

Scienjoy Holdings Corporation has revealed today that it has inked a cooperative agreement with China Mobile on November 1, 2020. The company disclosed...